Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT06161415

Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study

Led by Quan Dong Nguyen · Updated on 2025-05-14

12

Participants Needed

1

Research Sites

60 weeks

Total Duration

On this page

Sponsors

Q

Quan Dong Nguyen

Lead Sponsor

G

Global Ophthalmic Research Center (GORC)

Collaborating Sponsor

AI-Summary

What this Trial Is About

The LION Study is a prospective, single-center phase 1 clinical trial to evaluate the safety, tolerability, and distribution of Laquinimod administered as topical eye drops for two weeks in human participants.

CONDITIONS

Official Title

Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Able and willing to give informed consent and follow study instructions
  • Scheduled to undergo pars plana vitrectomy (PPV) or diagnostic vitrectomy
  • Intraocular pressure between 5 mmHg and 22 mmHg in the study eye
  • Women who are not pregnant or lactating, or are post-menopausal or sterilized
Not Eligible

You will not qualify if you...

  • Active periocular or ocular infectious disease such as blepharitis, scleritis, conjunctivitis, keratitis, or endophthalmitis
  • Active infectious uveitis
  • Intraocular or extraocular surgery within 90 days prior to enrollment
  • Intravitreal steroids in the study eye within 90 days prior to enrollment
  • Intravitreal VEGF inhibitor injections within 30 days prior to enrollment
  • Use of topical cyclosporine, corticosteroids, or calcineurin inhibitors in the study eye within 14 days prior to enrollment
  • Use of strong or moderate CYP3A4 inhibitors or inducers within 2 weeks before baseline visit and during the study
  • Any degree of hepatic impairment (Child-Pugh A, B, or C)
  • Moderate or severe renal impairment (GFR ≤60 mL/min)
  • History of HIV or other immunodeficiency disorders
  • History of acute hepatitis A, B, or C
  • History of organ or bone marrow transplant
  • Active malignancy under treatment
  • Any acute or chronic medical condition that could prevent safe participation
  • Currently enrolled in another clinical trial
  • Any condition preventing acquisition of required eye images

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Spencer Center for Vision Research at the Byers Eye Institute

Palo Alto, California, United States, 94303

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

5

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study | DecenTrialz